Aggressive pituitary lesion with a remarkably high Ki-67;Lesão pituitária agressiva com ki-67 notavelmente elevado

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 58, Issue 6, 2014, Pages 656-660

  Marques, Pedro ^a   Mafra, Manuela ^b   Calado, Carlos ^b   Martins, Anabela ^c   Monteiro, Joaquim ^b   Leite, Valeriano ^a  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^b Universidade de Lisboa   (Portugal)

^c Hospital Luz   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN;

CARCINOMA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FATALITY; FEMALE; HUMAN; HYPOPHYSIS; ISOLATION AND PURIFICATION; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PITUITARY NEOPLASMS; SEVERITY OF ILLNESS INDEX; SURGERY;

CARCINOMA; FATAL OUTCOME; FEMALE; HUMANS; KI-67 ANTIGEN; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; PITUITARY GLAND; PITUITARY NEOPLASMS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84907009470     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/0004-2730000003116     Document Type: Article

References (20)

1. Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab. 2010;95(10):4592-4599.
2. Asa SL, Ezzat S. The pathogenesis of pituitary tumors. Annu Rev Pathol. 2009;4:97-126.
3. Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volun- teers; occult adenomas in general population. Ann Intern Med. 1994;120(10):817-20.
4. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB. Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab. 2005;90(5):3089-3099.
5. Heaney AP. Clinical review: pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab. 2011;96(12):3649-3660.
6. Al-Shraim M, Asa SL. The 2004 World Health Organization classification of pituitary tumors: what is new? Acta Neuropathol. 2006;111(1):1-7.
7. Kaltsas GA, Mukherjee JJ, Plowman PN, Monson JP, Grossman AB, Besser GM. The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab. 1998;83(12):4233-4238.
8. Garrão AF, Sobrinho LG, Pedro-Oliveira, Bugalho MJ, Boavida JM, Raposo JF, et al. ACTH-producing carcinoma of the pituitary with haematogenic metastases. Eur J Endocrinol. 1997;137(2):176-80.
9. Dudziak K, Honegger J, Bornemann A, Horger M, Müssig K. Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course - Case report and review of literature. J Clin Endocrinol Metab. 2011;96(9):2665-9.
10. Ragel B, Couldwell W. Pituitary carcinoma: a review of literature. Neurosurg Focus. 2004;16(4):E7.
11. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery. 1996;38(1):99-106.
12. Dekkers OM, Pereira AM, Romijn JA. Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. J Clin Endo-crinol Metab. 2008;93(10):3717-26.
13. Freda PU, Wardlaw SL, Post KD. Unusual causes of sellar/para- sellar masses in a large transsphenoidal surgical series. J Clin Endocrinol Metab. 1996;81(10):3455-9.
14. Komninos J, Vlassopoulou V, Protopapa D, Korfias S, Konto- georgos G, Sakas DE, et al. Tumors metastatic to the pituitary gland: case report and literature review. J Clin Endocrinol Metab. 2004;89(2):574-80.
15. Iezzoni JC, Mills SE. “Undifferentiated” small round cell tumors of the sinonasal tract: differential diagnosis update. Am J Clin Pa- thol. 2005;124 Suppl:S110-121.
16. Dedeurwaerdere F, Giannini C, Sciot R, Rubin BP, Perilongo G, Borghi L, et al. Primary peripheral PNET/Ewing’s sarcoma of the dura: a clinicopathologic entity distinct from central PNET. Mod Pathol. 2002;15:673-8.
17. Sholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311-22.
18. Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV, Cusimano M. Ki-67 in pituitary neoplasms: a review--part I. Neurosurgery. 2009;65(3):429-37.
19. Sav A, Rotondo F, Syro LV, Scheithauer BW, Kovacs K. Biomarkers of pituitary neoplasms. Anticancer Res. 2012;32(11):4639-54.
20. Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H, et al. Pituitary carcinoma and aggressive pitui- tary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf). 2012;76(6):769-75.